Selected synthetic case / actual retained answers
A normal screening result can leave the relevant cell function untested
Both answers recognise the p40phox/NCF4 pattern. The educational question is why a normal soluble-stimulus assay can coexist with defective killing after a cell ingests a particle.
A selected synthetic development case, published by MontMedical. The clinical fingerprints match, but the exact prompts submitted to OpenEvidence were not independently retained. This is an editorial comparison of historical answers, not a blinded efficacy trial.
Our editorial assessment
How the retained answers rate.
OpenEvidence8.4/10
MontMedical8.4/10
Different strengths; the weighted scores are level.
Same five criteria and weights for both systems| Criterion and weight | OpenEvidence | MontMedical |
|---|
| Diagnosis and case fit 25% | 9/10 | 9/10 |
|---|
| Interpretation of tests and experiments 25% | 8/10 | 9/10 |
|---|
| Strength of the claims 20% | 7/10 | 8/10 |
|---|
| Decisions and next steps 15% | 9/10 | 7/10 |
|---|
| Clarity and teaching 15% | 9/10 | 8/10 |
|---|
Why each criterion received its mark
Diagnosis and case fit
OpenEvidence · 9/10: Correctly identifies the oxidase hypothesis and addresses both recorded meeting positions.
MontMedical · 9/10: Correctly integrates Crohn-like inflammation, selective killing and the B-cell result.
Interpretation of tests and experiments
OpenEvidence · 8/10: Explains stimulus and cell differences, but describes PMA independence and exclusive unmasking too categorically.
MontMedical · 9/10: Preserves the distinction between the normal soluble-stimulus test and unmeasured particle-triggered oxidase activity.
Strength of the claims
OpenEvidence · 7/10: The main distinction is sound; some mechanistic and treatment extrapolations are stronger than necessary.
MontMedical · 8/10: Keeps the genotype provisional and limits extrapolation from classic CGD.
Decisions and next steps
OpenEvidence · 9/10: Connects the diagnostic work-up directly to the pending infliximab decision.
MontMedical · 7/10: Identifies the appropriate assay gap but does not make the pending treatment decision equally explicit.
Clarity and teaching
OpenEvidence · 9/10: Strong physiological explanation and direct response to the clinicians’ actual disagreement.
MontMedical · 8/10: Focused sections aid inspection; the immediate clinical consequence could be easier to find.
AI-assisted editorial judgment of these historical texts, published by MontMedical. Read the rubric, anchors and limits. These are answer-quality scores, not measured diagnostic accuracy or patient benefit.
The actual retained wording
OpenEvidence vs MontMedical.
These are verbatim passages from the retained answers, not rewritten examples. Bold, link formatting and line breaks have been removed. Each labelled passage is contiguous; an excerpt may begin within a sentence. Our interpretation and scores are separate.
OpenEvidence
Retained 2026-09-24
Mechanistic account
PMA bypasses receptor signaling and directly activates protein kinase C, driving NADPH oxidase assembly independent of p40phox.
Next diagnostic step
Three "normal" DHR tests using PMA therefore cannot exclude this diagnosis — the correct next investigation is genetic testing of NCF4 and/or a particulate (opsonized S. aureus, serum-opsonized zymosan, or IgG-bead) phagosomal oxidase assay.
MontMedical
Retained 2026-09-24
Leading classification
most compatible with a variant NADPH oxidase defect, such as p40phox/NCF4 deficiency, rather than classic idiopathic Crohn disease alone, pending confirmatory molecular genetic testing.
Assay interpretation
A normal neutrophil oxidative burst following soluble phorbol myristate acetate stimulation does not exclude an inherited NADPH oxidase complex disorder, as variant deficiencies such as p40phox deficiency preserve soluble PMA-induced neutrophil reactive oxygen species generation while selectively impairing particle- or bacteria-induced oxidase activation; evaluating oxidase activity using opsonized particulate stimuli can help resolve this diagnostic gap.
The case and the decision
The teaching case combines Crohn-like inflammation, superficial infections, normal PMA-stimulated DHR screens, impaired killing after bacterial uptake and markedly reduced oxidase activity in an EBV-transformed B-cell line. The team is considering whether the normal screen excludes an oxidase defect and whether a classic CGD prognosis automatically applies.
The physiological explanation
A PMA-DHR assay asks how the cell responds to one soluble laboratory stimulus. It does not measure every step of oxidase activity around an ingested particle. In a 24-patient p40phox study, particle-triggered neutrophil activity and B-cell oxidase activity were impaired while PMA-DHR was normal or only mildly impaired. [1]
That is why the apparent contradiction is informative: the test conditions differ. Appropriate particle-based functional testing and NCF4 analysis address the remaining hypothesis more directly.
How the retained answers differ
Both tools explain the mismatch and reach the same leading hypothesis. MontMedical explicitly keeps genetic confirmation pending and separates assessment, assay limitations and research evidence. OpenEvidence more directly rejects the two meeting positions and connects the discussion to the proposed infliximab decision.
Its shorthand that PMA drives assembly independently of p40phox is stronger than needed. The useful, supported observation is stimulus- and cell-dependent impairment; the normal result is not a universal bypass rule.
What a fair comparison preserves
OpenEvidence's clear response to the actual treatment question is a strength. Conversely, a milder phenotype in one p40phox cohort cannot establish zero future infection risk for an unconfirmed individual. The retained pair illustrates the value of precise assay interpretation and a distinct immediate-decision section, rather than establishing a diagnostic victory for either tool.
For a slower explanation of the mechanism, read the annotated screening-test case.
Retained answer dates: MontMedical 2026-09-24; OpenEvidence 2026-09-24. Excerpt wording was checked against the retained answers; formatting was removed. These versions were selected during development. Complete original run settings and identical submitted prompts are not documented.
This article examines the MontMedical Pro beta using retained diagnostic answers.